Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | HTR1D | P28221 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19233139 | 0.76 | CA12 (0.41) | CA12CA9PDE3BPDE3ACA1 | |
| SCHEMBL29547698 | 0.76 | CA12 (0.41) | CA12CA9PDE3BPDE3ACA1 | |
| SCHEMBL17442949 | 0.76 | F11 (0.48) | CA12CA9PDE3BPDE3ACA1 | |
| SCHEMBL8345240 | 0.76 | SIRT2 (0.45) | CA12CA9PDE3BPDE3ACA1 | |
| SCHEMBL18237950 | 0.76 | CA12 (0.41) | CA12CA9PDE3BPDE3ACA1 | |
| SCHEMBL13104643 | 0.76 | KDM4E (0.44) | CA12CA9PDE3BPDE3ACA1 | |
| SCHEMBL30564985 | 0.76 | SIRT2 (0.45) | CA12CA9PDE3BPDE3ACA1 | |
| SCHEMBL13094338 | 0.76 | CA12 (0.44) | CA12CA9PDE3BPDE3ACA1 | |
| Hydrochloric Acid SCHEMBL28454847 | 0.74 | NCF1 (0.42) | CA12CA9PDE3BPDE3ACA1 | |
| SCHEMBL4056355 | 0.73 | PDE3B (0.43) | CA12CA9PDE3BPDE3ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | MSD K.K. (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1939194-A1 | BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-7235562-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | CA12 20/4885CA9 32/4885NOS1 3212/4885 |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | CA12 3462/4885CA9 4034/4885NOS1 2504/4885 |
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | PYCR1, CHRM1, MTR | CA12 4861/4885CA9 4870/4885NOS1 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.